

August 17, 2016



BioCorRx, Inc. Announces Agreement With Dr. David Gastfriend to Provide Strategic Initiative and Corporate Development Consulting

LOS ANGELES, CA -- (Marketwired) -- 08/17/16 -- [BioCorRx, Inc.](#) (OTC PINK: BICX), developer of the BioCorRx® Recovery Program, a Medication-Assisted Treatment (MAT) program, announces a consulting and advisory agreement with David R. Gastfriend, M.D. The agreement with Dr. Gastfriend is part of the Company's continued drive to expand core business development capabilities and regulatory support infrastructure. Dr. Gastfriend will facilitate potential strategic directions and partnerships as well as provide situation specific expertise to the Company with regard to regulatory approval processes.

"Dr. Gastfriend has become intimately familiar with the aspirations of BioCorRx as well as our current strategic initiatives. Equally as important, Dr. Gastfriend will be an invaluable asset as we navigate the regulatory pathway. Dr. Gastfriend's background at institutions such as the Massachusetts General Hospital Department of Psychiatry, the Treatment Research Institute, and the American Society of Addiction Medicine provide him a powerful base of experience and expertise with which to draw from. In his prior role as Vice President at Alkermes, he worked on pivotal efficacy studies and research on effectiveness, health services, criminal justice systems and health economics. To have access to a resource like Dr. Gastfriend is a luxury not often afforded to such young enterprises, so we are very pleased to have the opportunity to work with him," says BioCorRx President and CEO, Brady Granier. Gastfriend added, "BioCorRx is taking a unique approach to a national epidemic, by innovating both in formulation development and clinical care, in an integrated fashion. It's both novel and needed."

About BioCorRx

BioCorRx Inc. (OTC PINK: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment.

For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking

statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.

investors@BioCorRx.com

714-462-4880

Investor Relations:

MZ North America

Mike Cole

Vice President

Main: 949-259-4988

mike.cole@mzgroup.us

www.mzgroup.us

Source: BioCorRx, Inc.